Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE: 177Lu-Edotreotide vs Everolimus in GEP-NET
NCT03049189Phase 3Active, not recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Feb 2017
- Primary completion
- Nov 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 14
01
Overview
A Phase 3 trial of lutetium Lu 177-edotreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by ITM Isotope Technologies Munich. Started Feb 2017; status: active, not recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03049189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049189.